A detailed history of Sheaff Brock Investment Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Sheaff Brock Investment Advisors, LLC holds 44,546 shares of BMY stock, worth $2.53 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
44,546
Previous 33,159 34.34%
Holding current value
$2.53 Million
Previous $1.38 Million 67.39%
% of portfolio
0.2%
Previous 0.13%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$39.66 - $51.75 $451,608 - $589,277
11,387 Added 34.34%
44,546 $2.31 Million
Q2 2024

Jul 30, 2024

SELL
$40.25 - $52.99 $31,998 - $42,127
-795 Reduced 2.34%
33,159 $1.38 Million
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $38,767 - $43,955
808 Added 2.44%
33,954 $1.84 Million
Q4 2023

Feb 08, 2024

SELL
$48.48 - $57.85 $78,149 - $93,254
-1,612 Reduced 4.64%
33,146 $1.7 Million
Q3 2023

Nov 08, 2023

SELL
$57.89 - $64.73 $134,825 - $150,756
-2,329 Reduced 6.28%
34,758 $2.02 Million
Q2 2023

Aug 08, 2023

SELL
$63.71 - $70.74 $175,584 - $194,959
-2,756 Reduced 6.92%
37,087 $2.37 Million
Q1 2023

May 01, 2023

SELL
$65.71 - $74.53 $85,882 - $97,410
-1,307 Reduced 3.18%
39,843 $2.76 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $24,447 - $28,949
-357 Reduced 0.86%
41,150 $2.96 Million
Q3 2022

Nov 03, 2022

BUY
$0.13 - $76.84 $102 - $60,857
792 Added 1.95%
41,507 $2.95 Million
Q2 2022

Aug 02, 2022

SELL
$72.62 - $79.98 $259,616 - $285,928
-3,575 Reduced 8.07%
40,715 $3.14 Million
Q1 2022

May 06, 2022

SELL
$61.48 - $73.72 $770,098 - $923,416
-12,526 Reduced 22.05%
44,290 $3.23 Million
Q4 2021

Feb 03, 2022

SELL
$53.63 - $62.52 $63,926 - $74,523
-1,192 Reduced 2.05%
56,816 $3.54 Million
Q3 2021

Nov 03, 2021

SELL
$59.17 - $69.31 $4.28 Million - $5.02 Million
-72,417 Reduced 55.52%
58,008 $3.43 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $16,468 - $17,933
-266 Reduced 0.2%
130,425 $8.72 Million
Q1 2021

May 11, 2021

SELL
$59.34 - $66.74 $17,861 - $20,088
-301 Reduced 0.23%
130,691 $8.25 Million
Q4 2020

Feb 01, 2021

BUY
$57.74 - $65.43 $669,264 - $758,399
11,591 Added 9.71%
130,992 $8.13 Million
Q3 2020

Oct 30, 2020

SELL
$57.43 - $63.64 $2.18 Million - $2.42 Million
-38,040 Reduced 24.16%
119,401 $7.2 Million
Q2 2020

Aug 07, 2020

SELL
$54.82 - $64.09 $2,905 - $3,396
-53 Reduced 0.03%
157,441 $9.26 Million
Q1 2020

Apr 30, 2020

SELL
$46.4 - $67.43 $737,342 - $1.07 Million
-15,891 Reduced 9.17%
157,494 $8.78 Million
Q4 2019

Jan 29, 2020

BUY
$49.21 - $64.19 $7.12 Million - $9.29 Million
144,781 Added 506.16%
173,385 $11.1 Million
Q3 2019

Oct 28, 2019

SELL
$42.77 - $50.71 $13,002 - $15,415
-304 Reduced 1.05%
28,604 $1.45 Million
Q2 2019

Jul 31, 2019

SELL
$44.62 - $49.34 $4.46 Million - $4.93 Million
-99,986 Reduced 77.57%
28,908 $1.31 Million
Q1 2019

Apr 29, 2019

BUY
$45.12 - $53.8 $76,704 - $91,460
1,700 Added 1.34%
128,894 $6.15 Million
Q4 2018

Jan 28, 2019

SELL
$48.76 - $63.23 $59,926 - $77,709
-1,229 Reduced 0.96%
127,194 $6.61 Million
Q3 2018

Nov 09, 2018

SELL
$55.19 - $62.25 $65,179 - $73,517
-1,181 Reduced 0.91%
128,423 $7.97 Million
Q2 2018

Jul 31, 2018

SELL
$50.53 - $62.98 $99,392 - $123,881
-1,967 Reduced 1.5%
129,604 $7.17 Million
Q1 2018

May 03, 2018

BUY
$59.92 - $68.98 $146,744 - $168,932
2,449 Added 1.9%
131,571 $8.32 Million
Q4 2017

Feb 12, 2018

SELL
$59.94 - $65.35 $1.48 Million - $1.62 Million
-24,730 Reduced 16.07%
129,122 $7.91 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $5.12 Million - $5.91 Million
92,715 Added 151.65%
153,852 $9.81 Million
Q2 2017

Aug 09, 2017

BUY
N/A
61,137
61,137 $3.41 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $121B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Sheaff Brock Investment Advisors, LLC Portfolio

Follow Sheaff Brock Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sheaff Brock Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sheaff Brock Investment Advisors, LLC with notifications on news.